AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01578551
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy
Trial: NCT01578551
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
Trial: NCT01578551
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg twice daily with food.
Trial: NCT04891679
Drug: Oral misoprostol solution (OMS)
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity.
Trial: NCT03063450
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
Trial: NCT00963729
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00963729
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00963729
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02447991
Drug: Rizatriptan
RxNorm normalized name: Rizatriptan
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
Trial: NCT01243385
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
Trial: NCT04108039
Drug: GnRh antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
Trial: NCT04108039
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
Trial: NCT01187589
Drug: Nebulizer & Albuterol 0.5ml
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosolized by a nebulizer
Trial: NCT02087462
Drug: Voltaren
RxNorm normalized name: Voltaren
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks.
Trial: NCT02087462
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks.
Trial: NCT03734198
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
Trial: NCT03734198
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
Trial: NCT01242904
Drug: icodextrin
RxNorm normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
Trial: NCT00452335
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mcg capsule once daily (QD)
Trial: NCT00452335
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mcg capsule twice daily (BID)
Trial: NCT00452335
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mcg capsule twice daily (BID)
Trial: NCT02932397
Drug: Intravenous dose of 0.5 mg/kg of propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04465175
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second dose magnesium sulphate infusion over one hour
Trial: NCT00568308
Drug: PI-88
RxNorm normalized name: Heparanase inhibitor PI-88
DrugBank: Muparfostat (DB05808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg subcutaneous injection
Trial: NCT04346615
Drug: Zavegepant (BHV-3500)
RxNorm normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intranasal (IN) for 14 days
Trial: NCT00002604
Drug: O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
Trial: NCT00002604
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
Trial: NCT03062800
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100-200mg/d,oral ,qn
Trial: NCT03062800
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (500mg/m\^2) on day 1 of 21-days cycle,ivgtt
Trial: NCT03062800
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (75mg/m\^2) on day 1 of 21-days cycle, ivgtt
Trial: NCT03062800
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (AUC=5) on day 1 of 21-days cycle, ivgtt
Trial: NCT02383758
Drug: Glycerin Suppository
RxNorm normalized name: Leader Pediatric Glycerin Suppository
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
Trial: NCT02383758
Drug: Bisacodyl suppository
RxNorm normalized name: bisacodyl Rectal Suppository
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
Trial: NCT02383758
Drug: Senna
RxNorm normalized name: Senna
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
Trial: NCT01111656
Drug: Interferon beta-1b group
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive interferon beta-1b 250ug subcutaneously every other day
Trial: NCT01111656
Drug: Interferon beta-1b/Atorvastatin group
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
Trial: NCT03475160
Drug: Sildenafil Citrate vaginal suppositories
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
Trial: NCT02787356
Drug: TDS Lidocaine 5%; generic
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDS Lidocaine 5%; generic
Trial: NCT02787356
Drug: TDS Lidocaine 5%; RLD
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDS Lidocaine 5%; RLD
Trial: NCT00194012
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Addressed in arm description.
Trial: NCT01587326
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram 10 mg/d to 20 mg/d
Trial: NCT00000189
Drug: Gepirone
RxNorm normalized name: Gepirone
DrugBank: Gepirone (DB12184)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218062
Drug: D-Amphetamine 30mg
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218062
Drug: D-Amphetamine 60mg
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218062
Drug: Modafinil 200mg
RxNorm normalized name: MODAFINIL 200MG TAB
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00218062
Drug: Modafinil 400mg
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00864500
Drug: Clobetasol Propionate 0.05% lotion, single exposure
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A: Experimental Subjects received Alpharma USPD, Inc formulated products
Trial: NCT00634647
Drug: Satraplatin
RxNorm normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/m\^2 days 1-5 of every 35 day cycle
Trial: NCT00634647
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg twice daily every 35 days
Trial: NCT04293887
Drug: Recombinant human interferon α1β
RxNorm normalized name: Interferon beta, recombinant human
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
Trial: NCT03919175
Drug: Umbralisib
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
Trial: NCT03919175
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
Trial: NCT04031885
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT04031885
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IM
Trial: NCT02123407
Drug: Carbon Nanoparticles
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
Trial: NCT03592472
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
Trial: NCT03592472
Drug: Abexinostat
RxNorm normalized name: Abexinostat
DrugBank: Abexinostat (DB12565)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
Trial: NCT01663272
Drug: CABOZANTINIB
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
Trial: NCT01663272
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
Trial: NCT04667819
Drug: Sodium Hyaluronate
RxNorm normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
Trial: NCT00145509
Drug: Asenapine
RxNorm normalized name: Asenapine
DrugBank: Asenapine (DB06216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
Trial: NCT02661438
Drug: Placebo to Ciprofloxacin DPI (BAYQ3939)
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
Trial: NCT02922452
Drug: BMS-986141
RxNorm normalized name: BMS-986141
DrugBank: BMS-986141 (DB14942)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose BMS-986141 and Multiple doses of Dilitazem
Trial: NCT01341184
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300 mg orally on days 20-41
Trial: NCT01341184
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg orally on days 20-41
Trial: NCT00394966
Drug: SCH 619734 Dose 1
RxNorm normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Trial: NCT00394966
Drug: SCH 619734 Dose 2
RxNorm normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Trial: NCT00394966
Drug: SCH 619734 Dose 3
RxNorm normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Trial: NCT00394966
Drug: SCH 619734 Dose 4
RxNorm normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Trial: NCT03909776
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
Trial: NCT03354429
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
Trial: NCT02285985
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets: 5 mg
Trial: NCT04537806
Drug: Brexanolone
RxNorm normalized name: Brexanolone
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as IV infusion.
Trial: NCT02568488
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850 mg orally twice daily for 6 months
Trial: NCT02477020
Drug: TAK-063 20 mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 tablet.
Trial: NCT02845271
Drug: fixed combination of paracetamol + tramadol hydrochloride
RxNorm normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT02285751
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02285751
Drug: prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02285751
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no